|
1
|
American Cancer Society, . American Cancer
Society Facts and Figures-2022. American Cancer Society, Inc.;
Atlanta, GA: 2022
|
|
2
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel SA, Ndabbahaliye A, Lim PK, Milton R
and Rameshwar P: Challenges in the development of future treatments
for breast cancer stem cells. Breast Cancer (Dove Med Press).
2:1–11. 2010.PubMed/NCBI
|
|
5
|
Hong M, Tan HY, Li S, Cheung F, Wang N,
Nagamatsu T and Feng Y: Cancer stem cells: Potential targets of
Chinese medicines and their active compounds. Int J Mol Sci.
17:8932016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manogaran P, Umapathy D, Karthikeyan M,
Venkatachalam K and Singarvelu A: Dietary phytochemicals as a
potential source of targeting cancer stem cells. Cancer Invest.
39:349–368. 2021.PubMed/NCBI
|
|
7
|
Meerson A, Khatib S and Mahjna J: Natural
products targeting cancer stem cells for augmenting cancer
therapeutics. Int J Mol Sci. 22:130442021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naujokat C and McKee DL: The ‘Big Five’
phytochemicals targeting cancer stem cells: Curcumin, EGCG,
sulforaphane, resveratrol and genistein. Cur Med Chem.
28:4321–4342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Telang N: Natural phytochemicals as
testable therapeutic alternatives for HER-2-enriched breast cancer
(review). World Acad Sci J. 2:192020.
|
|
10
|
Telang NT, Nair HB and Wong GYC: Growth
inhibitory efficacy of Chinese herbs in a cellular model for
triple-negative breast cancer. Pharmaceuticals (Basel).
14:13182021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye L, Jia Y, Ji KE, Saunders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in
prevention and treatment of breast cancer and metastasis. Oncol
Lett. 10:1240–1250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Telang N: The divergent effects of ovarian
steroid hormones in the MCF-7 model for Luminal A breast cancer:
Mechanistic leads for therapy. Int J Mol Sci. 23:48002022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Telang N: Anti-proliferative and
pro-apoptotic effects of rosemary and constituent terpenoids in a
model for the HER-2-enriched molecular subtype of clinical breast
cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI
|
|
14
|
Moy B and Goss PE: Estrogen receptor
pathway: Resistance to endocrine therapy and new therapeutic
approaches. Clin Cancer Res. 12:4790–4793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Hara J, Vareslija D, McBrian J, Bane F,
Tibbits P, Byrne C, Conroy RM, Hao Y, Gaorra PÓ, Hill ADK, et al:
AIB1:ERα transcriptional activity is selectively enhanced in
aromatase inhibitor-resistant breast cancer cells. Clin Cancer Res.
18:3305–3315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Russo J and Russo IH: The role of estrogen
in the initiation of breast cancer. J Steroid Biochem Mol Biol.
102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Santen RJ, Yue W and Wang JP: Estrogen
metabolites and breast cancer. Steroids. 99:61–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gupta M, McDougal A and Safe S: Estrogenic
and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites
of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J
Steroid Biochem Mol Biol. 67:413–419. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suto A, Telang NT, Tanino H, Takeshita T,
Ohmiya H, Osborne MP and Kubota T: In vitro and in vivo modulation
of growth regulation in the human breast cancer cell line MCF-7 by
estradiol metabolites. Breast Cancer. 6:87–92. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mukherjee B, Telang N and Wong GYC: Growth
inhibition of estrogen receptor positive human breast cancer cells
by Taheebo from the inner bark of Tabebuia avellanedae tree.
Int J Mol Med. 24:253–260. 2009.PubMed/NCBI
|
|
21
|
Hole S, Pedersen AM, Hansen SK, Lundqvist
J, Yde CW and Lykkesfeldt AE: New cell culture model for aromatase
inhibitor-resistant breast cancer shows sensitivity to fulvestrant
treatment and cross-resistance between letrozole and exemestane.
Int J Oncol. 46:1481–1490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sabnis G and Brodie A: Understanding
resistance to endocrine agents: Molecular mechanisms and potential
for intervention. Clin Breast Cancer. 10:E6–E15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Telang N, Nair HB and Wong GYC: Growth
inhibitory efficacy and anti-aromatase activity of Tabebuia
avellanedae in a model for post-menopausal Luminal A breast
cancer. Biomed Rep. 11:222–229. 2019.PubMed/NCBI
|
|
24
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yarden Y and Pines G: The ERBB network: At
last, cancer therapy meets systems biology. Nat Rev Cancer.
12:553–563. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Artega CL and Engelman JA: ERBB receptors:
From oncogene discovery to basic science to mechanism-based cancer
therapeutics. Cancer Cell. 25:282–303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Otto T and Sicinski P: Cell cycle proteins
as promising agents in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bosco EE and Knudson ES: RB in breast
cancer: At the crossroads of tumorigenesis and treatment. Cell
Cycle. 6:667–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cox LA, Chen G and Lee EY: Tumor
suppressor genes and their role in breast cancer. Breast Cancer Res
Treat. 32:19–38. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tait SWG and Green DR: Mitochondrion and
cell death: Outer membrane permeabillization and beyond. Nat Rev
Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ichim G and Tait SWG: A fate worse than
death: Apoptosis as an oncogenic process. Nat Rev Cancer.
16:539–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Telang N, Nair HB and Wong GYC:
Anti-proliferative and pro-apoptotic effects of Dipsacus
asperoides in a cellular model for triple-negative breast
cancer. Arch Breast Cancer. 9:66–75. 2022. View Article : Google Scholar
|
|
34
|
Soterou D and Fuchs Y: A matter of life
and death: Stem cell survival in tissue regeneration and tumour
formation. Nat Rev Cancer. 18:187–201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lytle NK, Barber AG and Reya T: Stem cell
fate in cancer growth, progression and therapy resistance. Nat Rev
Cancer. 18:669–680. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park IH, Zhou R, West JA, Yabuchi A, Huo
H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of
human somatic cells to pluripotency with defined factors. Nature.
151:141–146. 2008. View Article : Google Scholar
|
|
37
|
Yu J, Hu K, Smuga-Otto K, Tian S, Stuart
R, Slukvin II and Thompson JA: Human induced pluripotent cells free
of vector and transgene sequences. Science. 324:797–801. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Telang N: Stem cell models for cancer
therapy. Int J Mol Sci. 23:70552022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Muniraj N, Siddharth S and Sharma D:
Bioactive compounds: Multi-targeting silver bullets for preventing
and treating breast cancer. Cancers (Basel). 11:15632019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Velloso FJ, Bianco AFR, Farias JO, Torres
NEC, Ferruzo PYM, Anschau V, Jesus-Ferreira HC, Chng THT, Sogayar
MC, Zerbini LF and Correa RG: The crossroads of breast cancer
progression: Insights into the modulation of major signaling
pathways. Onco Targets Ther. 10:5491–5524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rushing BR, Wiggs A, Molina S, Schroder M
and Sumner S: Metabolomics analysis reveals novel targets of
chemosensitizing polyphenols and omega-3 polyunsaturated fatty
acids in triple negative breast cancer cells. Int J Mol Sci.
24:44062023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao S, Zhang X, Liu J, Ji F, Zhang Z, Meng
Q, Zhang Q, Han X, Wu H, Yin Y, et al: Icariin induces
triple-negative breast cancer cell apoptosis and suppresses
invasion by inhibiting the JNK/c-Jun signaling pathway. Drug Des
Devel Ther. 17:821–836. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liskova A, Kubatka P, Samec M, Zubor P,
Mlyneck M, Bielik T, Samuel SM, Zulli A, Kwon TK and Büsselberg D:
Dietary phytochemicals targeting cancer stem cells. Molecules.
24:8992019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dalasanur Nagaprashantha L, Adhikari R,
Singhal J, Chikara S, Awasthi S, Horne D and Singhal SS:
Translational opportunities for broad-spectrum natural
phytochemicals and targeted agent combinations in breast cancer.
Int J Cancer. 142:658–670. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Won KI and Spruck C: Triple-negative
breast cancer therapy: Current and future perspectives (review).
Int J Oncol. 57:1245–1261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang Z, Zhang Q, Yu L, Zhu J, Cao Y and
Gao X: The signaling pathways and targets of traditional Chinese
medicine and natural medicine in triple-negative breast cancer. J
Ethnopharmacol. 264:1132492021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arzi L, Mollaei H and Hoshyar R:
Countering triple-negative breast via impeding Wnt/β-catenin
signaling, a phytotherapeutic approach. Plants (Basel).
11:21912022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinreich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 226:2011–2015. 1994. View Article : Google Scholar
|
|
49
|
Hannen R and Bartsch JW: Essential roles
of telomerase reverse transcriptase hTERT in cancer stemness and
metastasis. FEBS Lett. 592:2023–2031. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ganesan K and Xu B: Telomerase inhibitors
from natural products and their anticancer potential. Int J Mol
Sci. 19:132017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Relitti N, Saraswati AP, Frederico S, Khan
T, Brindisi M, Zisterer D, Brogi S, Gemma S, Butini S and Campiani
G: Telomerase based cancer therapeutics: A review on their clinical
trials. Cur Top Med Chem. 20:433–457. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fragiadaki P, Ranieri E, Kalliantasi K,
Kouvida E, Apaliki E, Vakonaki E, Mamoulakis C, Spandidos DA and
Tsatsakis A: Τelomerase inhibitors and activators in aging and
cancer: A systematic review. Mol Med Rep. 25:1582022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kumar VE, Nambiar R, De Souza C, Nguyen A,
Chien J and Lam KS: Targeting epigenetic modifiers of tumor
plasticity and cancer stem cell behavior. Cells. 11:14032022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gooding AJ and Scheiman WP:
Epithelial-mesenchymal transition programs and cancer stem cell
phenotypes: Mediators of breast cancer therapy resistance. Mol
Cancer Res. 18:1257–1270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jin W: Role of JAK/STAT3 signaling in the
regulation of metastasis, the transition of cancer stem cells, and
chemoresistance of cancer by epithelial-mesenchymal transition.
Cells. 9:2172020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bruna A, Rueda OM, Greenwood W, Batra AS,
Callari M, Batra RN, Pogrebniac K, Sandoval J, Cassidy JW,
Tufegdzik-Vidakovic A, et al: A biobank of breast cancer explants
with preserved intra-tumor heterogeneity to screen anticancer
compounds. Cell. 167:260–274.e22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sachs N, De Ligt J, Kopper O, Gogola E,
Buovnova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Drost J and Clevers H: Organoids in cancer
research. Nat Rev Cancer. 18:407–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cao J, Chan WC and Chow MSS: Use of
conditional reprogramming cell, patient derived xenograft and
organoid for drug screening for individualized prostate cancer
therapy: Current and future perspectives (review). Int J Oncol.
60:522022. View Article : Google Scholar : PubMed/NCBI
|
